Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Descending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
81864-0103-30 81864-0103 Momelotinib Ojjaara 100.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Sept. 15, 2023 In Use
50242-0210-12 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 28, 2022 In Use
50242-0210-60 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-83 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-86 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 15, 2020 Feb. 11, 2022 In Use
50242-0210-90 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
16729-0223-61 16729-0223 temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug. 13, 2018 In Use
46026-0983-01 46026-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Intravenous Nov. 5, 2009 May 28, 2010 No Longer Used
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-13 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-61 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
51991-0821-28 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0821-33 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0822-28 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0822-33 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0823-28 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0823-33 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0824-28 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
51991-0824-33 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63850-0058-01 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0058-04 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
63850-0059-01 63850-0059 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0059-04 63850-0059 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
63850-0060-01 63850-0060 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0060-04 63850-0060 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
63850-0061-01 63850-0061 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
63850-0061-04 63850-0061 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
00093-7769-24 00093-7769 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 23, 2023 In Use
73150-0200-12 73150-0200 umbralisib UKONIQ 260.2 mg/1 Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Oral Feb. 5, 2021 July 31, 2023 No Longer Used
50419-0385-01 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Sept. 14, 2017 In Use
50419-0385-72 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Oct. 30, 2018 In Use
71779-0115-01 71779-0115 duvelisib Copiktra 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0115-02 71779-0115 duvelisib Copiktra 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0125-01 71779-0125 duvelisib Copiktra 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0125-02 71779-0125 duvelisib Copiktra 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2018 Aug. 31, 2024 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2020 Aug. 31, 2024 In Use
69656-0103-90 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral March 27, 2017 May 31, 2022 In Use
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 Dec. 31, 2025 In Use
69660-0202-91 69660-0202 Rucaparib Rubraca 250.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral May 1, 2017 July 31, 2025 In Use
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 July 31, 2025 In Use
00069-0252-30 00069-0252 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0353-30 00069-0353 Talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0454-30 00069-0454 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0546-30 00069-0546 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0655-30 00069-0655 Talazoparib Talzenna 0.75 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0757-30 00069-0757 Talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00245-0822-30 00245-0822 Everolimus TORPENZ 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0823-30 00245-0823 Everolimus TORPENZ 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0824-30 00245-0824 Everolimus TORPENZ 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0825-30 00245-0825 Everolimus TORPENZ 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
70377-0010-22 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0010-11 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-22 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0011-11 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-23 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0012-22 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0012-11 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0012-23 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0013-22 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0013-11 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0013-23 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
71332-0006-12 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
71332-0006-60 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
71332-0006-90 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
82950-0001-16 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0001-20 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0001-24 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0012-01 82950-0012 Tovorafenib OJEMDA 25.0 mg/ml Chemotherapy Enzyme Inhibitor BRAF, CRAF ORAL April 30, 2024 In Use
82959-0111-01 82959-0111 imetelstat sodium RYTELO 188.0 mg/1 Chemotherapy Enzyme Inhibitor Telomerase Intravenous June 6, 2024 In Use
82959-0112-01 82959-0112 imetelstat sodium RYTELO 47.0 mg/1 Chemotherapy Enzyme Inhibitor Telomerase Intravenous June 6, 2024 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug. 25, 2011 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug. 18, 2017 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous June 10, 2019 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous April 23, 2020 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sept. 18, 2020 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
51144-0020-01 51144-0020 ENFORTUMAB VEDOTIN PADCEV 20.0 mg/2mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sept. 20, 2021 In Use
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sept. 7, 2017 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct. 24, 2018 Sept. 30, 2024 In Use
79952-0110-01 79952-0110 loncastuximab tesirine ZYNLONTA 10.0 mg/2mL Immunotherapy Drug Antibody Conjugate CD19 Intravenous April 30, 2021 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug. 5, 2020 June 30, 2024 No Longer Used
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 100.0 mg/20mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov. 14, 2022 In Use
00078-0017-05 00078-0017 Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Aug. 1, 2013 No Longer Used
00078-0017-15 00078-0017 Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Aug. 1, 2013 No Longer Used
00078-0102-05 00078-0102 Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Nov. 1, 2014 No Longer Used
00078-0102-15 00078-0102 Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Nov. 1, 2014 No Longer Used
00574-0106-01 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00574-0106-03 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00781-2119-01 00781-2119 Bromocriptine Mesylate Bromocriptine Mesylate Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Nov. 30, 2013 No Longer Used

Found 10,000 results in 7 milliseconds — Export these results